alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 6,551–6,575 of 15,839 studies scoring 30–49 out of 100 (page 263 of 634) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Examining the diagnostic value of the mnemonic discrimination task for classification of cognitive status and amyloid-beta burden

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neuropsychologia 2023-11-07

Alzheimer's disease (AD) is the most common type of dementia, characterized by early memory impairments and gradual worsening of daily functions. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

The Feasibility of Using Smartphone Sensors to Track Insomnia, Depression, and Anxiety in Adults and Young Adults: Narrative Review

✓ Peer-reviewed alzhub usefulness score 43 out of 100. JMIR mHealth and uHealth 2023-02-17

Extreme sleepiness and insomnia not only influence physical health, they also have a significant impact on mental health, such as by causing depression, which has a prevalence of 18% to 21% among young adults aged 16 to 24 in the United Kingdom. 2 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source

Effects of Smartphone-Based Compensatory Cognitive Training and Physical Activity on Cognition, Depression, and Self-Esteem in Women with Subjective Cognitive Decline

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Brain sciences 2021-08-01

Subjective cognitive decline is a symptom that may appear in the early stages of Alzheimer's disease. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

A novel tablet-based software for the acquisition and analysis of gaze and eye movement parameters: a preliminary validation study in Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in neurology 2023-06-15

The idea that eye movements can reflect certain aspects of brain function and inform on the presence of neurodegeneration is not a new one. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Revised Criteria for Diagnosis and Staging of Alzheimer's Disease: Alzheimer's Association Workgroup

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer's & Dementia 2024-06-27

This Alzheimer's Association workgroup paper proposes a major update to how Alzheimer's disease is diagnosed: it defines the disease by biological markers (amyloid plaques and tau tangles detected via blood, CSF, or PET) rather than requiring clinical symptoms like memory loss to be present. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

FDA approval of the Lumipulse G pTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Annals of Medicine and Surgery 2025-12-17

This review article discusses the FDA's May 2025 clearance of Fujirebio's Lumipulse G blood test, the first FDA-cleared blood test for aiding Alzheimer's diagnosis (via the pTau217/beta-amyloid 1-42 ratio). 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

GUIDE and Beyond: Strategies for Comprehensive Dementia Care Integration

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of the American Geriatrics Society 2025-11

Written by leaders of six established comprehensive dementia-care programs (including Care Ecosystem, MIND at Home, and BRI Care Consultation) that helped shape the CMS GUIDE model, this paper lays out a practical four-step roadmap for organizations trying to launch or sustain comprehensive dementia care programs like GUIDE. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer's & Dementia 2018-04

This influential 2018 paper proposed defining Alzheimer's disease by what is happening biologically in the brain (amyloid plaques, tau tangles, and neuron loss, measured by scans or spinal fluid tests) instead of by memory symptoms alone. 4 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source

Blots on a field?

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Science 2022-07-21

Science journalist Charles Piller, working with neuroscientist Matthew Schrag and independent image-forensics experts, published a six-month investigation finding apparent digital manipulation (duplicated bands, spliced images) in Western blot figures from papers by Sylvain Lesné, including his highly influential 2006 Nature paper proposing that a specific amyloid protein (Aβ*56) causes memory loss. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

Caspase-1 inhibition improves cognition without significantly altering amyloid and inflammation in aged Alzheimer disease mice

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Cell death & disease 2022-10-11

Human genetic and animal model studies indicate that brain microglial inflammation is a primary driver of cognitive impairment in Alzheimer Disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2018-05-31

The concentration of 124 I-RmAb158-scFv8D3, as measured in vivo with PET, increased with age and corresponded well with the ex vivo autoradiography and Aβ immunohistochemistry results. 5 key findings →

Design: clinical trial Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Acta neuropathologica communications 2016-02-25

The hTau40(AT) mice mimic pathological hallmarks of tauopathies including a cognitive phenotype combined with pronounced neuroinflammation visible by bioluminescence. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Fluvoxamine maleate alleviates amyloid-beta load and neuroinflammation in 5XFAD mice to ameliorate Alzheimer disease pathology

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Frontiers in immunology 2024-07-29

Our data suggest that FXN ameliorates AD pathology, by simultaneously targeting two key pathological features: Aβ deposits and neuroinflammation. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of neurology 2024-12-12

Plasma ptau217 has strong diagnostic performance in distinguishing CSF biomarker-defined AD in a clinically relevant, younger cohort of people with symptoms, adding further weight for a simple diagnostic blood test for AD as a cause of a patient's symptoms. 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Current Alzheimer research 2007-04-01

Alzheimer disease (AD) includes inflammatory processes in the senile plaques and surrounding glia, with increased expression of acute phase proteins such as C-reactive protein (CRP) and IL-6. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review

✓ Peer-reviewed alzhub usefulness score 42 out of 100. European journal of medicinal chemistry 2019-03-08

Plant iridoids such as catalpol and its 10-O-trans-p-coumaroyl derivative, geniposide, harpagoside, and loganin, and seco-iridoids, oleuropein and its aglycone and oleocanthal have been found to exhibit significant neuroprotective effect and the property of slowing down the process of neurogedeneration in AD and PD. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Human molecular genetics 1997-10-01

Overexpression of Alzheimer amyloid precursor protein (APP) produces dramatically different phenotypes in transgenic mice depending on the genetic background. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Neuroscience letters 1995-03-01

We measured the activities of choline acetyltransferase (ChAT) in the post mortem frontal cortex in 32 Alzheimer's disease (AD) patients with different apolipoprotein E (apoE) genotypes. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed